{
  "question_stem": {
    "en": "A 36-year-old man comes to the office after he was found to have an abnormal lipid panel during employee wellness testing at his company. He has no prior medical problems and takes no medications. The patient is a software technician and has a sedentary lifestyle. He eats mostly fast foods, rarely exercises, and drinks 2-3 cans of beer daily. His BMI is 31 kg/m². Physical examination is unremarkable. Results of laboratory studies performed in the office are as follows:\n\nTotal cholesterol 290 mg/dL\nHigh-density lipoprotein 45 mg/dL\nLow-density lipoprotein 110 mg/dL\nTriglycerides 675 mg/dL\n\nLifestyle modification with a balanced diet, regular exercise, and reduced alcohol intake is advised. He is also started on fenofibrate therapy. This medication is most likely to help the patient by which of the following mechanisms? {{exhibit_1}}",
    "zh": "一名36岁的男性因在公司员工健康检查中发现脂质异常而前来就诊。他既往没有医学问题，也没有服用药物。患者是一名软件技术员，生活方式久坐不动。他主要吃快餐，很少运动，每天喝2-3罐啤酒。他的BMI为31 kg/m²。体格检查无特殊发现。在诊室进行的实验室研究结果如下：\n\n总胆固醇 290 mg/dL\n高密度脂蛋白 45 mg/dL\n低密度脂蛋白 110 mg/dL\n甘油三酯 675 mg/dL\n\n建议改变生活方式，包括均衡饮食、规律运动和减少饮酒。他还开始服用非诺贝特治疗。该药物最有可能通过以下哪种机制帮助患者？ {{exhibit_1}}"
  },
  "question": {
    "en": "This medication is most likely to help the patient by which of the following mechanisms?",
    "zh": "该药物最有可能通过以下哪种机制帮助患者？"
  },
  "options": {
    "A": {
      "en": "Blocking intestinal cholesterol absorption",
      "zh": "阻断肠道胆固醇吸收"
    },
    "B": {
      "en": "Decreasing hepatic cholesterol synthesis",
      "zh": "减少肝脏胆固醇合成"
    },
    "C": {
      "en": "Increasing fecal loss of cholesterol derivatives",
      "zh": "增加粪便中胆固醇衍生物的流失"
    },
    "D": {
      "en": "Inhibiting LDL receptor degradation",
      "zh": "抑制LDL受体降解"
    },
    "E": {
      "en": "Reducing hepatic VLDL production",
      "zh": "减少肝脏VLDL的产生"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "This patient has a moderately elevated (>500 mg/dL) triglyceride level, which is associated with an increased risk of cardiovascular disease. Lifestyle modifications (increased aerobic exercise, decreased alcohol and total caloric intake) can decrease triglycerides, but moderate (or worse) hypertriglyceridemia usually requires pharmacologic therapy.\n\nLipoprotein lipase (LPL) hydrolyzes triglycerides in chylomicrons and VLDL to release free fatty acids, which can be used for energy or converted back to triglycerides for storage in adipose tissue. It also facilitates the transfer of triglycerides from these lipoproteins to HDL. Fibrates (eg, gemfibrozil, fenofibrate) activate peroxisome proliferator-activated receptor alpha (PPAR-α), which leads to decreased hepatic VLDL production and increased LPL activity. They are able to decrease triglyceride levels by 25%-50% and increase HDL by 5%-20%. Fish oil supplements containing high concentrations of omega-3 fatty acids also decrease VLDL production, and inhibit synthesis of apolipoprotein B as well. These supplements lower triglycerides and can be used as an alternate treatment for patients with moderate hypertriglyceridemia.\n\n(Choices A, C, and D) Ezetimibe selectively blocks intestinal cholesterol absorption. Bile acid-binding resins (eg, cholestyramine) increase fecal loss of cholesterol derivatives by binding bile acids in the intestine and disrupting enterohepatic bile acid circulation. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors are monoclonal antibodies that reduce LDL receptor degradation in the liver. These drugs are used primarily in patients with elevated cholesterol levels but have minimal effect on triglyceride levels.\n\n(Choice B) Statins (eg, atorvastatin) decrease hepatic cholesterol synthesis by inhibiting HMG-CoA reductase. Statins have a modest effect on triglyceride levels and are recommended for patients with mild to moderate hypertriglyceridemia.\n\nEducational objective:\nFibrates lower triglyceride levels by activating peroxisome proliferator-activated receptor alpha, which leads to decreased hepatic VLDL production and increased lipoprotein lipase activity. Fish oil supplements containing high concentrations of omega-3 fatty acids lower triglycerides by decreasing production of VLDL and apolipoprotein B.",
    "zh": "该患者甘油三酯水平中度升高（>500 mg/dL），这与心血管疾病的风险增加有关。生活方式的改变（增加有氧运动，减少酒精和总热量摄入）可以降低甘油三酯，但中度（或更严重）高甘油三酯血症通常需要药物治疗。\n\n脂蛋白脂肪酶 (LPL) 水解乳糜微粒和 VLDL 中的甘油三酯，释放游离脂肪酸，这些脂肪酸可用于能量或转化为甘油三酯储存在脂肪组织中。它还促进甘油三酯从这些脂蛋白转移到HDL。贝特类药物（例如，吉非贝齐、非诺贝特）激活过氧化物酶体增殖物激活受体α (PPAR-α)，这会导致肝脏 VLDL 产生减少和 LPL 活性增加。它们能够将甘油三酯水平降低 25%-50%，并将 HDL 升高 5%-20%。含有高浓度 omega-3 脂肪酸的鱼油补充剂也会减少 VLDL 的产生，并抑制载脂蛋白 B 的合成。这些补充剂可以降低甘油三酯，可用作中度高甘油三酯血症患者的替代治疗方法。\n\n（选项 A、C 和 D）依折麦布选择性地阻断肠道胆固醇吸收。胆汁酸结合树脂（例如，考来烯胺）通过在肠道内结合胆汁酸并破坏肝肠胆汁酸循环来增加粪便中胆固醇衍生物的流失。前蛋白转化酶枯草杆菌蛋白酶 kexin 9 (PCSK9) 抑制剂是单克隆抗体，可减少肝脏中 LDL 受体的降解。这些药物主要用于胆固醇水平升高的患者，但对甘油三酯水平的影响很小。\n\n（选项 B）他汀类药物（例如，阿托伐他汀）通过抑制 HMG-CoA 还原酶来降低肝脏胆固醇合成。他汀类药物对甘油三酯水平有适度影响，建议用于轻度至中度高甘油三酯血症患者。\n\n教学目标：\n贝特类药物通过激活过氧化物酶体增殖物激活受体α来降低甘油三酯水平，这会导致肝脏 VLDL 产生减少和脂蛋白脂肪酶活性增加。含有高浓度 omega-3 脂肪酸的鱼油补充剂通过减少 VLDL 和载脂蛋白 B 的产生来降低甘油三酯。"
  },
  "summary": {
    "en": "This question tests knowledge of hypertriglyceridemia management and the mechanism of action of fibrates. Fibrates are PPAR-alpha agonists that decrease hepatic VLDL production and increase lipoprotein lipase activity, leading to lower triglyceride levels.\n\nTo solve this question, recognize the patient's elevated triglyceride level and the use of fenofibrate. Recall that fibrates primarily lower triglycerides by reducing VLDL production in the liver.",
    "zh": "此问题测试关于高甘油三酯血症的管理以及贝特类药物的作用机制的知识。贝特类药物是 PPAR-α 激动剂，可减少肝脏 VLDL 的产生并增加脂蛋白脂肪酶活性，从而降低甘油三酯水平。\n\n要解决这个问题，需要认识到患者甘油三酯水平升高以及使用非诺贝特。回想一下，贝特类药物主要通过减少肝脏中 VLDL 的产生来降低甘油三酯。"
  },
  "tags": "Hypertriglyceridemia; Lipid metabolism; Fenofibrate; PPAR-alpha; VLDL; Cardiology; Endocrinology",
  "category": "CVS",
  "question_id": "11844",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\11844",
  "extracted_at": "2025-11-05T11:51:29.663045",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:44:36.349599",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}